Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Other financing activities (2020 - 2023)

Alx Oncology Holdings' Other financing activities history spans 4 years, with the latest figure at $112000.0 for Q2 2023.

  • For Q2 2023, Other financing activities fell 27.74% year-over-year to $112000.0; the TTM value through Jun 2023 reached $494000.0, down 64.79%, while the annual FY2025 figure was $14000.0, 99.14% down from the prior year.
  • Other financing activities for Q2 2023 was $112000.0 at Alx Oncology Holdings, down from $222000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $12.5 million in Q4 2020 and bottomed at $5000.0 in Q3 2022.
  • The 4-year median for Other financing activities is $299000.0 (2020), against an average of $1.5 million.
  • The largest annual shift saw Other financing activities skyrocketed 78.26% in 2021 before it plummeted 99.06% in 2022.
  • A 4-year view of Other financing activities shows it stood at $12.5 million in 2020, then plummeted by 95.76% to $530000.0 in 2021, then tumbled by 58.11% to $222000.0 in 2022, then crashed by 49.55% to $112000.0 in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Other financing activities are $112000.0 (Q2 2023), $222000.0 (Q4 2022), and $5000.0 (Q3 2022).